To convert the meeting times to your local time Click Here
Industry Hall 1
Libtayo is the first immunotherapy to demonstrate an improvement in overall survival in advanced cervical cancer, as well as progression-free survival and objective response rate, compared to chemotherapy. Improvements in overall survival were seen in the overall population and both squamous cell carcinoma and adenocarcinoma subgroups. It is important to explore the significance of this trial, its applicability to clinical practice and management of any adverse events.